1. Home
  2. WNW vs EOCN Comparison

WNW vs EOCN Comparison

Compare WNW & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meiwu Technology Company Limited

WNW

Meiwu Technology Company Limited

N/A

Current Price

$2.37

Market Cap

4.5M

ML Signal

N/A

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$3.15

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WNW
EOCN
Founded
2018
2000
Country
China
Israel
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
3.6M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
WNW
EOCN
Price
$2.37
$3.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 51.5K
4.4K
Earning Date
11-04-2026
09-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.14
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$3.33
52 Week High
$13.52
$3.80

Technical Indicators

Market Signals
Indicator
WNW
EOCN
Relative Strength Index (RSI) 45.04 48.21
Support Level $2.30 N/A
Resistance Level $2.75 $3.80
Average True Range (ATR) 0.13 0.21
MACD 0.01 0.00
Stochastic Oscillator 8.13 34.05

Price Performance

Historical Comparison
WNW
EOCN

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Share on Social Networks: